Alan J. Main - Feb 28, 2022 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
EVP, Innov & Chem Sciences
Signature
/s/ Alan J. Main, Ph.D.
Stock symbol
LXRX
Transactions as of
Feb 28, 2022
Transactions value $
-$56,305
Form type
4
Date filed
2/28/2022, 06:16 PM
Previous filing
Feb 14, 2022
Next filing
Feb 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +22.4K +15.9% 163K Feb 28, 2022 Direct F1
transaction LXRX Common Stock Options Exercise +23.3K +14.29% 186K Feb 28, 2022 Direct F1
transaction LXRX Common Stock Options Exercise +8.98K +4.82% 195K Feb 28, 2022 Direct F1
transaction LXRX Common Stock Tax liability -$56.3K -19.8K -10.11% $2.85 176K Feb 28, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -22.4K -100% 0 Feb 28, 2022 Common Stock 22.4K Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -23.3K -50% 23.3K Feb 28, 2022 Common Stock 23.3K Direct F1, F4
transaction LXRX Restricted Stock Units Options Exercise -8.98K -33.33% 18K Feb 28, 2022 Common Stock 8.98K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter.
F4 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.